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failure and associated with the risk to cardiovascular disease in meta-
bolic syndrome, low plasma PTX3 concentrations were observed in
patients with coronary artery disease and associated with metabolic
syndrome and non-vascular injury resulted from previous myocardial
infarction [4]. These studies reﬂect different roles for PTX3 in distinct
inﬂammatory diseases and suggest that PTX3 may be a marker of clini-
cal progression in heart diseases.
Considering the potential role for PTX3 as a risk factor for cardiovas-
cular diseases and that no laboratory marker is available to indicateChagas disease (CD) is a tropical neglected disease caused by
Trypanosoma cruzi, which affects more than 8 million people in Latin
America and represents an emerging problem in North America and
Europe due to international migrations. Although most individuals
infected by T. cruzi remain asymptomatic in the indeterminate form,
after 10–20 years they may progress to one of the symptomatic forms
of the disease, developing chronic chagasic cardiomyopathy (CCC),
digestive megasyndromes, or both [1].
Cytokines and inﬂammatory mediators, including the complement
system, are considered to contribute to the clinical progression
of chronic CD. Even though the activation of complement system is
essential to reduce parasite load during acute T. cruzi infection, it can
cause tissue injury due to inﬂammation in CCC [2].
PTX3 is a multifunctional soluble pattern recognition molecule of
innate immunity, which belongs to the long pentraxin family. Different-
ly from C reactive protein, which is a short pentraxin produced in the
liver. PTX3 is secreted at inﬂammatory sites by several cells, such as
monocytes/macrophages and endothelial cells [3]. Thus, PTX3 has
been considered a novel and probably more useful inﬂammatory mark-
er for cardiovascular diseases.
Recent studies have demonstrated the involvement of PTX3 in
different clinical disorders including cardiovascular diseases. WhileSaúde, Hospital de Clínicas,
, 80060-900 Curitiba, PR, Brazil.
Reaso).
eliability and freedom from bias
.high PTX3 plasma levels were related to cardiac commitment in heart
the progression from indeterminate to symptomatic CD, we aimed
to determine PTX3 plasma levels in chronic CD patients (n = 128)
from Southern Brazil using an ELISA commercial kit (Human Pentraxin
3/TSG-14, R&D®System, Minneapolis, USA). The cardiac patients were
graded according to the cardiac insufﬁciency classiﬁcation of the
American Heart Association, adapted for Chagas disease (2005) [5] in
A, B1, B2, C, and D groups. Demographical, laboratorial, and clinical
ﬁndings of the speciﬁc CD forms are shown in Table 1. Moreover, 87
unrelated Southern Brazilians with negative T. cruzi serology and
without clinical complaints were used as control subjects. All parame-
ters were analyzed with adjustment for age, sex, and ancestry using
logistic regression analysis. Formal written consent was obtained from
each individual and the study was approved by the local medical ethics
committee.
Plasma levels of PTX3 were signiﬁcantly lower in CD patients when
compared to controls (p b 0.0001, medians: 1.6 ng/ml and 2.7 ng/ml,
respectively) (Fig. 1A). Although PTX3 levels were not related with
cardiac commitment (cardiac A form versus B1 + B2 + C + D forms),
different PTX3 levels were observed in the cardiac group when com-
pared to indeterminate patients and controls (p b 0.0001). Moreover,
a positive correlation between plasma PTX3 and Left Ventricular
Ejection Fraction (LVEF) (rho = 0.29 and p = 0.0048) (Fig. 1B) was
observed in the patients. There was a positive correlation between
PTX3 levels and age in the controls (rho = 0.37, p = 0.0027), but not
in patients and PTX3 levels were related with low HDL levels
(b40 mg/dl) (1.72 ng/ml for low-HDL and 1.65 ng/ml for high-HDL,
p b 0.001, OR 0.72, and CI 95%: 0.63–0.83) (Fig. 1C). In addition, PTX3
levels were also related to body mass index in patients (BMI) (rho =
0.22 and p = 0.05), with PTX3 levels being lower in non-obese
(BMI b 30 kg/m2) than obese (BMI ≥ 30 kg/m2) CD patients (medians
1.42 ng/ml and 2.01 ng/ml, respectively, OR 1.67 CI 95%: 0.45–6.15
p= 0.04) (Fig. 1D).
Table 1
Clinical, demographical, and laboratorial features of the patients with chronic Chagas disease.
Parameters Chagas disease clinical form
Indeterminate
N = 41
Cardiac
N = 52
Digestive
N = 19
Cardiodigestive
N = 16
Age (years) Mean (min–max) 53.2 [34–69] 56.5 [34–84] 59.2 [36–84] 58.9 [37–73]
Sex Female 28 25 15 7
Male 13 27 4 9
Body mass index (kg/m2) (N) mean [min–max] (34) 26.7 [19.5–36.6] (30) 26.3 [18–35.5] (16) 25.1 [18.4–31.2] (4) 24.4 [20.8–27.9]
Predominant ancestry Euro–Brazilian 36 34 12 13
Afro–Brazilian 5 14 6 3
Amerindian 0 3 1 0
Asian–Brazilian 0 1 0 0
Cardiac commitment A N.a. 14 N.a. 6
B1 N.a. 11 N.a. 5
B2 N.a. 2 N.a. 0
C N.a. 23 N.a. 5
D N.a. 2 N.a. 0
Left ventricular fraction ejection (%) (N) mean [min–max] (27) 69 [59–78] (41) 53.5 [24–82] N.a. (12) 56.3 [23–75]
Glucose (mg/dl) (N) mean [min–max] (29) 102.9 [77–239] (38) 105.5 [82–373] (14) 109.4 [89–162] (11) 100.2 [88–115]
Total cholesterol (mg/dl) (N) mean [min–max] (31) 207.1 [124–272] (42) 205.4 [120–331] (11) 208.2 [157–267] (12) 188.2 [119–253]
LDL cholesterol (mg/dl) (N) mean [min–max] (31) 131 [59.2–200.4] (42) 156.3 [85–283] (11) 160.4 [117–228] (12) 140.8 [69–183]
HDL cholesterol (mg/dl) (N) mean [min–max] (31) 53.5 [28–80] (42) 49 [27–114] (11) 47.8 [31–70] (12) 47.3 [29–76]
Triglycerides (mg/dl) (N) mean [min–max] (31) 112.4 [46–229] (42) 140.2 [50–584] (11) 140.7 [65–283] (12) 115.5 [60–179]
History of diabetes (N) 3/35 3/49 2/18 1/16
History of hypertension N.a. 22/35 23/49 10/18 6/16
Note: The functional classiﬁcation of cardiac insufﬁciency according to Brazilian Consensus on Chagas disease (2005): A: altered electrocardiogram (ECG) and normal echocardiogram
(ECHO), absence of cardiac insufﬁciency (CI); B1: altered ECG, LVEF N45%, absence of CI; B2: altered ECHO, LVEF b45%, absence of CI; C: altered ECG and ECHO, compensable CI;D: altered
ECG and ECHO, refractory CI. Data is shown as numbers or mean [range]. N.a.: not applicable.
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one side protecting against unwanted complement activation, and on
the other hand, enhancing complement-mediated tissue injury in situa-
tions such as ischemia or reperfusion [6].
PTX3 may mediate complement activation through the binding to
different pattern recognition molecules including C1q, ﬁcolins, and
mannose-binding lectin (MBL) [6]. A pro-inﬂammatory role for MBLFig. 1. Plasma PTX3 levels in patients with Chagas disease and its relation to risk factors for c
subjects (*p b 0.0001, Kruskal–Wallis test); and in cardiac and indeterminate Chagas disease form
in high and lowHDL patients (p b 0.001). C. Correlation between PTX3 plasma levels and left ve
levels (ng/ml) and BMI (%): rho 0.22 and p= 0.05.has been suggested in CCC and binding of both MBL and Ficolin-2 to
T. cruziwas demonstrated in vitro [2]. On the other hand, PTX3may in-
teract with Factor H remaining functionally active, thus surface-bound
PTX3/Factor Hmay prevent tissue damage associatedwith complement
activation. Thus, low levels of PTX3 in patients with chronic CD may re-
ﬂect an anti-inﬂammatory role for the protein, which might be in part
related with Factor H interaction. Additionally, an anti-inﬂammatoryardiovascular disease. A. PTX3 plasma levels in patients with Chagas disease and control
s comparedwith control subjects (*p b 0.0001,MannWhitney test).B. PTX3plasma levels
ntricular ejection fraction (LVEF) in patients with CD.D.Association between PTX3 plasma
235K.C.F. Lidani et al. / International Journal of Cardiology 190 (2015) 233–235property for PTX3 has been reported in cardiac surgery and during
clearance of late apoptotic cells by macrophages [7]. Moreover, exoge-
nous administration of PTX3 was found to restrict the inﬂammatory
response in experimental chronic granulomatous disease [8]. Low levels
of PTX3 related to absence of disease activitywere also found in system-
ic lupus erythematosus patients [9]. These studies corroborate with our
ﬁndings indicating that PTX3might play an anti-inﬂammatory property
in chronic CD, conferring a cardioprotective role.
In contrast, high PTX3 concentrations were related to heart failure,
contributing to cardiac commitment deﬁnition and associated with
severity of dilative cardiomyopathy. Besides, increased PTX3 levels
were observed in cardiac acute processes such as myocardial infarction
and unstable angina [10]. Thus, these ﬁndings reﬂect different features
of PTX3 in inﬂammatory process and suggest its use to assess clinical
progression in cardiac disease.
Interestingly, we found a signiﬁcant correlation of PTX3 with LVEF,
which is an important cardiac function parameter. Although the patho-
physiological role of PTX3 in the immune response is still unknown, this
study suggests a protective role for PTX3 in chronic CD, being associated
with cardioprotective function. Since low PTX3 concentration was also
observed in CCC, it seems that low plasma PTX3 levels may be associat-
ed with cardiovascular risk factors in chronic CD.
In conclusion, our ﬁndings suggest an immunoregulatory role
associatedwith cardioprotective feature for PTX3 in chronic CD. Further
prospective studies shouldmonitor plasma PTX3 levels in the follow-up
of chronic patients with CD in order to conﬁrm this effect of PTX3.
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